2 cheap stocks I think Warren Buffett would love

As a long-term investor, I could do a lot worse than listen to a stock-investing genius like Warren Buffett. Here are two top stocks I think he’d approve of.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Warren Buffett is one of the most successful, and by extension most famous, value-loving investors in the business. Picking low-cost stocks with his Berkshire Hathaway firm and watching them balloon in value has made the ‘Sage of Omaha’ worth an estimated $100.4bn today.

But Buffett’s investing strategy is about much more than just identifying undervalued stocks. Here are two cheap UK shares I think would whet the billionaire investor’s appetite for other reasons.

The FTSE 100 pharma giant

Buying companies which have clear and effective ‘economic moats’ is a cornerstone of Buffett’s money-making strategy. This is the name given to any long-term advantage a business has over the competition. They can include anything from market-leading products and a lower cost base versus rival operators, to creating high switching costs for customers looking to take their custom elsewhere.

GlaxoSmithKline (LSE: GSK) has one of the most formidable economic moats out there, namely significant patent protection. This stops rival drugs manufacturers moving in and copying its expensively-assembled portfolio of world-class treatments. According to DrugPatentWatch, the FTSE 100 company has 1,048 product patents in effect spanning 59 countries.

Pharmaceuticals development is a notoriously difficult business. And GlaxoSmithKline’s great track record of producing market-leading patented products is no guarantee of future success. But I’d argue that this UK share’s undemanding forward price-to-earnings (P/E) ratio of around 13 times still offers terrific value. Especially considering its strong position in many fast-growing therapy areas like oncology, vaccines and respiratory disorders, and the enormous financial clout it has to plough into R&D.

I think Buffett, who already owns Merck and Bristol Myers Squibb, would love this UK share.

Another stock Warren Buffett might adore

The popularity of Britvic’s (LSE: BVIC) brands seems to be timeless. The likes of Pepsi, Robinsons, Lipton and R Whites have been keeping consumers refreshed for many decades (some even have their roots in the 1800s). And their popularity is a strong as ever.

Buffett loves firms with robust brand power, as shown by Berkshire Hathaway’s holdings in Apple, Kraft Heinz and Coca-Cola. This economic moat helps demand for their products grow stronger than the broader market when consumer spending comes under pressure. It also allows companies like Britvic to raise prices without having to worry too much about how this will affect sales volumes.

I think Britvic’s a top buy despite the threat posed by a growing carbon dioxide shortage, a critical component in the company’s fizzy drinks. European fertilizer plants are shutting down operations in response to soaring energy prices, including two major facilities here in the UK. This could naturally damage beverages production and jack up costs considerably.

City analysts currently think Britvic’s earnings will jump 24% in the upcoming financial year (to September 2022). This leaves it trading on a bargain-basement forward price-to-earnings growth (PEG) ratio of 0.7. In my opinion, this provides the sort of bang for your buck that value investors like Warren Buffett adore.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended Apple and Bristol Myers Squibb. The Motley Fool UK has recommended Britvic and GlaxoSmithKline and has recommended the following options: long March 2023 $120 calls on Apple and short March 2023 $130 calls on Apple. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Man hanging in the balance over a log at seaside in Scotland
Investing Articles

Will Lloyds shares rise 25% or 39% by this time next year?

Lloyds shares are expected to rebound after sinking to fresh multi-month peaks. Royston Wild considers the outlook for the FTSE…

Read more »

Modern suburban family houses with car on driveway
Investing Articles

£7,500 invested in Taylor Wimpey shares 18 months ago is now worth…

A raft of issues have been plaguing the housebuilding sector in the last year-and-a-half. How bad was the damage for…

Read more »

A rear view of a female in a bright yellow coat walking along the historic street known as The Shambles in York, UK which is a popular tourist destination in this Yorkshire city.
Investing Articles

£210 drip-fed into this 6.8%-yielding UK stock could lead to a £1,000 second income 

This FTSE 100 dividend stock has slumped nearly 11% inside two weeks, making it a worthy candidate to consider for…

Read more »

ISA Individual Savings Account
Investing Articles

ISA or SIPP? 2 factors to consider

As next month's ISA contribution deadline creeps up, our writer considers a couple of key differences between using a SIPP,…

Read more »

Portrait of pensive bearded senior looking on screen of laptop sitting at table with coffee cup.
Investing Articles

Is this 5.6% yielding dividend share a brilliant defensive bolthole as war rages?

Harvey Jones looks at a FTSE 100 dividend share with a brilliant record of delivering income and growth, and wonders…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

2 quality UK stocks trading below intrinsic value?

UK stocks have a reputation for being cheap, but could value investors be in dreamland with the opportunities being presented…

Read more »

Businessman with tablet, waiting at the train station platform
Investing Articles

£15,000 put into Greggs shares a year ago is worth this much now…

Greggs' sausage rolls may be tasty enough -- but its shares have left a bad taste in some investors' mouths…

Read more »

Investing Articles

FTSE 100 drops sharply — are serious bargains emerging in UK stocks?

Andrew Mackie looks at the FTSE 100 and explores how sharp falls, market volatility, and structural opportunities are reshaping the…

Read more »